aluates Reports

$ 0.0

Automative

Transthyretin Amyloidosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: December 2024

Report Code: QYRE-Auto-30K12346

Global Transthyretin Amyloidosis Treatment Market Research Report 2022

BUY CHAPTERS

Transthyretin Amyloidosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-30K12346

Report

December 2024

Pages:118

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Pfizer Inc

Johnson & Johnson Services Inc.

Ionis Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Bristol Myers Squibb Company

Acrotech Biopharma

Astrazeneca plc

Astellas Pharma Inc

Prothena

SOM Biotech

BridgeBio Pharma, Inc.

Transthyretin Amyloidosis Treatment - Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Transthyretin Amyloidosis Treatment - Market

The growth is attributed to the extensive research in the development of new therapies and the presence of robust pipeline drugs that are used to treat transthyretin.

The global market for Transthyretin Amyloidosis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Transthyretin Amyloidosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Transthyretin Amyloidosis Treatment by region & country, by Type, and by Application.

The Transthyretin Amyloidosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transthyretin Amyloidosis Treatment.

Market Segmentation

Scope of Transthyretin Amyloidosis Treatment - Market Report

Report Metric	Details
Report Name	Transthyretin Amyloidosis Treatment - Market
CAGR	5%
Segment by Type:	ATTR-PN ATTR-CM
Segment by Application	Hospital Pharmacies Specialty Pharmacies Retail Pharmacies Online Pharmacies
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Transthyretin Amyloidosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Transthyretin Amyloidosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Transthyretin Amyloidosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Transthyretin Amyloidosis Treatment - Market report?

Ans: The main players in the Transthyretin Amyloidosis Treatment - Market are Pfizer Inc., Johnson & Johnson Services, Inc., Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., BridgeBio Pharma, Inc., Bristol-Myers Squibb Company, Acrotech Biopharma, AstraZeneca, Astellas Pharma, Inc., Prothena, SOM Biotech

What are the Application segmentation covered in the Transthyretin Amyloidosis Treatment - Market report?

Ans: The Applications covered in the Transthyretin Amyloidosis Treatment - Market report are Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies

What are the Type segmentation covered in the Transthyretin Amyloidosis Treatment - Market report?

Ans: The Types covered in the Transthyretin Amyloidosis Treatment - Market report are ATTR-PN, ATTR-CM

Recommended Reports

Rare & Neuro Diseases

Cardiovascular Treatments

Other Drug Therapies

1 Market Overview

1.1 Transthyretin Amyloidosis Treatment Product Introduction

1.2 Global Transthyretin Amyloidosis Treatment Market Size Forecast

1.3 Transthyretin Amyloidosis Treatment Market Trends & Drivers

1.3.1 Transthyretin Amyloidosis Treatment Industry Trends

1.3.2 Transthyretin Amyloidosis Treatment Market Drivers & Opportunity

1.3.3 Transthyretin Amyloidosis Treatment Market Challenges

1.3.4 Transthyretin Amyloidosis Treatment Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Transthyretin Amyloidosis Treatment Players Revenue Ranking (2023)

2.2 Global Transthyretin Amyloidosis Treatment Revenue by Company (2019-2024)

2.3 Key Companies Transthyretin Amyloidosis Treatment Manufacturing Base Distribution and Headquarters

2.4 Key Companies Transthyretin Amyloidosis Treatment Product Offered

2.5 Key Companies Time to Begin Mass Production of Transthyretin Amyloidosis Treatment

2.6 Transthyretin Amyloidosis Treatment Market Competitive Analysis

2.6.1 Transthyretin Amyloidosis Treatment Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Transthyretin Amyloidosis Treatment Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis Treatment as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 ATTR-PN

3.1.2 ATTR-CM

3.2 Global Transthyretin Amyloidosis Treatment Sales Value by Type

3.2.1 Global Transthyretin Amyloidosis Treatment Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Transthyretin Amyloidosis Treatment Sales Value, by Type (2019-2030)

3.2.3 Global Transthyretin Amyloidosis Treatment Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital Pharmacies

4.1.2 Specialty Pharmacies

4.1.3 Retail Pharmacies

4.1.4 Online Pharmacies

4.2 Global Transthyretin Amyloidosis Treatment Sales Value by Application

4.2.1 Global Transthyretin Amyloidosis Treatment Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Transthyretin Amyloidosis Treatment Sales Value, by Application (2019-2030)

4.2.3 Global Transthyretin Amyloidosis Treatment Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Transthyretin Amyloidosis Treatment Sales Value by Region

5.1.1 Global Transthyretin Amyloidosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Transthyretin Amyloidosis Treatment Sales Value by Region (2019-2024)

5.1.3 Global Transthyretin Amyloidosis Treatment Sales Value by Region (2025-2030)

5.1.4 Global Transthyretin Amyloidosis Treatment Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

5.2.2 North America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

5.3.2 Europe Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

5.4.2 Asia Pacific Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

5.5.2 South America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

5.6.2 Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value

6.3 United States

6.3.1 United States Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

6.3.2 United States Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

6.4.2 Europe Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

6.5.2 China Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

6.5.3 China Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

6.6.2 Japan Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

6.7.2 South Korea Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

6.8.2 Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Transthyretin Amyloidosis Treatment Sales Value, 2019-2030

6.9.2 India Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

6.9.3 India Transthyretin Amyloidosis Treatment Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Pfizer Inc.

7.1.1 Pfizer Inc. Profile

7.1.2 Pfizer Inc. Main Business

7.1.3 Pfizer Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.1.4 Pfizer Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.1.5 Pfizer Inc. Recent Developments

7.2 Johnson & Johnson Services, Inc.

7.2.1 Johnson & Johnson Services, Inc. Profile

7.2.2 Johnson & Johnson Services, Inc. Main Business

7.2.3 Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.2.4 Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.2.5 Johnson & Johnson Services, Inc. Recent Developments

7.3 Ionis Pharmaceuticals, Inc.

7.3.1 Ionis Pharmaceuticals, Inc. Profile

7.3.2 Ionis Pharmaceuticals, Inc. Main Business

7.3.3 Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.3.4 Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.3.5 Alnylam Pharmaceuticals, Inc. Recent Developments

7.4 Alnylam Pharmaceuticals, Inc.

7.4.1 Alnylam Pharmaceuticals, Inc. Profile

7.4.2 Alnylam Pharmaceuticals, Inc. Main Business

7.4.3 Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.4.4 Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.4.5 Alnylam Pharmaceuticals, Inc. Recent Developments

7.5 BridgeBio Pharma, Inc.

7.5.1 BridgeBio Pharma, Inc. Profile

7.5.2 BridgeBio Pharma, Inc. Main Business

7.5.3 BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.5.4 BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.5.5 BridgeBio Pharma, Inc. Recent Developments

7.6 Bristol-Myers Squibb Company

7.6.1 Bristol-Myers Squibb Company Profile

7.6.2 Bristol-Myers Squibb Company Main Business

7.6.3 Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.6.4 Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.6.5 Bristol-Myers Squibb Company Recent Developments

7.7 Acrotech Biopharma

7.7.1 Acrotech Biopharma Profile

7.7.2 Acrotech Biopharma Main Business

7.7.3 Acrotech Biopharma Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.7.4 Acrotech Biopharma Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.7.5 Acrotech Biopharma Recent Developments

7.8 AstraZeneca

7.8.1 AstraZeneca Profile

7.8.2 AstraZeneca Main Business

7.8.3 AstraZeneca Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.8.4 AstraZeneca Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.8.5 AstraZeneca Recent Developments

7.9 Astellas Pharma, Inc.

7.9.1 Astellas Pharma, Inc. Profile

7.9.2 Astellas Pharma, Inc. Main Business

7.9.3 Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.9.4 Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.9.5 Astellas Pharma, Inc. Recent Developments

7.10 Prothena

7.10.1 Prothena Profile

7.10.2 Prothena Main Business

7.10.3 Prothena Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.10.4 Prothena Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.10.5 Prothena Recent Developments

7.11 SOM Biotech

7.11.1 SOM Biotech Profile

7.11.2 SOM Biotech Main Business

7.11.3 SOM Biotech Transthyretin Amyloidosis Treatment Products, Services and Solutions

7.11.4 SOM Biotech Transthyretin Amyloidosis Treatment Revenue (US$ Million) & (2019-2024)

7.11.5 SOM Biotech Recent Developments

8 Industry Chain Analysis

8.1 Transthyretin Amyloidosis Treatment Industrial Chain

8.2 Transthyretin Amyloidosis Treatment Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Transthyretin Amyloidosis Treatment Sales Model

8.5.2 Sales Channel

8.5.3 Transthyretin Amyloidosis Treatment Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Pfizer Inc

Johnson & Johnson Services Inc.

Ionis Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Bristol Myers Squibb Company

Acrotech Biopharma

Astrazeneca plc

Astellas Pharma Inc

Prothena

SOM Biotech

BridgeBio Pharma, Inc.

List of Tables

Table 1. Transthyretin Amyloidosis Treatment Market Trends

Table 2. Transthyretin Amyloidosis Treatment Market Drivers & Opportunity

Table 3. Transthyretin Amyloidosis Treatment Market Challenges

Table 4. Transthyretin Amyloidosis Treatment Market Restraints

Table 5. Global Transthyretin Amyloidosis Treatment Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Transthyretin Amyloidosis Treatment Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Transthyretin Amyloidosis Treatment Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Transthyretin Amyloidosis Treatment Product Type

Table 9. Key Companies Time to Begin Mass Production of Transthyretin Amyloidosis Treatment

Table 10. Global Transthyretin Amyloidosis Treatment Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transthyretin Amyloidosis Treatment as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Transthyretin Amyloidosis Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Transthyretin Amyloidosis Treatment Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Transthyretin Amyloidosis Treatment Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Transthyretin Amyloidosis Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Transthyretin Amyloidosis Treatment Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Transthyretin Amyloidosis Treatment Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Transthyretin Amyloidosis Treatment Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Transthyretin Amyloidosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2019-2024) & (%)

Table 27. Global Transthyretin Amyloidosis Treatment Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value, (2025-2030) & (US$ Million)

Table 31. Pfizer Inc. Basic Information List

Table 32. Pfizer Inc. Description and Business Overview

Table 33. Pfizer Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 34. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Pfizer Inc. (2019-2024)

Table 35. Pfizer Inc. Recent Developments

Table 36. Johnson & Johnson Services, Inc. Basic Information List

Table 37. Johnson & Johnson Services, Inc. Description and Business Overview

Table 38. Johnson & Johnson Services, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 39. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Johnson & Johnson Services, Inc. (2019-2024)

Table 40. Johnson & Johnson Services, Inc. Recent Developments

Table 41. Ionis Pharmaceuticals, Inc. Basic Information List

Table 42. Ionis Pharmaceuticals, Inc. Description and Business Overview

Table 43. Ionis Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 44. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Ionis Pharmaceuticals, Inc. (2019-2024)

Table 45. Ionis Pharmaceuticals, Inc. Recent Developments

Table 46. Alnylam Pharmaceuticals, Inc. Basic Information List

Table 47. Alnylam Pharmaceuticals, Inc. Description and Business Overview

Table 48. Alnylam Pharmaceuticals, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 49. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Alnylam Pharmaceuticals, Inc. (2019-2024)

Table 50. Alnylam Pharmaceuticals, Inc. Recent Developments

Table 51. BridgeBio Pharma, Inc. Basic Information List

Table 52. BridgeBio Pharma, Inc. Description and Business Overview

Table 53. BridgeBio Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 54. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of BridgeBio Pharma, Inc. (2019-2024)

Table 55. BridgeBio Pharma, Inc. Recent Developments

Table 56. Bristol-Myers Squibb Company Basic Information List

Table 57. Bristol-Myers Squibb Company Description and Business Overview

Table 58. Bristol-Myers Squibb Company Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 59. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Bristol-Myers Squibb Company (2019-2024)

Table 60. Bristol-Myers Squibb Company Recent Developments

Table 61. Acrotech Biopharma Basic Information List

Table 62. Acrotech Biopharma Description and Business Overview

Table 63. Acrotech Biopharma Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 64. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Acrotech Biopharma (2019-2024)

Table 65. Acrotech Biopharma Recent Developments

Table 66. AstraZeneca Basic Information List

Table 67. AstraZeneca Description and Business Overview

Table 68. AstraZeneca Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 69. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of AstraZeneca (2019-2024)

Table 70. AstraZeneca Recent Developments

Table 71. Astellas Pharma, Inc. Basic Information List

Table 72. Astellas Pharma, Inc. Description and Business Overview

Table 73. Astellas Pharma, Inc. Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 74. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Astellas Pharma, Inc. (2019-2024)

Table 75. Astellas Pharma, Inc. Recent Developments

Table 76. Prothena Basic Information List

Table 77. Prothena Description and Business Overview

Table 78. Prothena Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 79. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of Prothena (2019-2024)

Table 80. Prothena Recent Developments

Table 81. SOM Biotech Basic Information List

Table 82. SOM Biotech Description and Business Overview

Table 83. SOM Biotech Transthyretin Amyloidosis Treatment Products, Services and Solutions

Table 84. Revenue (US$ Million) in Transthyretin Amyloidosis Treatment Business of SOM Biotech (2019-2024)

Table 85. SOM Biotech Recent Developments

Table 86. Key Raw Materials Lists

Table 87. Raw Materials Key Suppliers Lists

Table 88. Transthyretin Amyloidosis Treatment Downstream Customers

Table 89. Transthyretin Amyloidosis Treatment Distributors List

Table 90. Research Programs/Design for This Report

Table 91. Key Data Information from Secondary Sources

Table 92. Key Data Information from Primary Sources

Table 93. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Transthyretin Amyloidosis Treatment Product Picture

Figure 2. Global Transthyretin Amyloidosis Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)

Figure 4. Transthyretin Amyloidosis Treatment Report Years Considered

Figure 5. Global Transthyretin Amyloidosis Treatment Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Transthyretin Amyloidosis Treatment Revenue in 2023

Figure 7. Transthyretin Amyloidosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. ATTR-PN Picture

Figure 9. ATTR-CM Picture

Figure 10. Global Transthyretin Amyloidosis Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 11. Global Transthyretin Amyloidosis Treatment Sales Value Market Share by Type, 2023 & 2030

Figure 12. Product Picture of Hospital Pharmacies

Figure 13. Product Picture of Specialty Pharmacies

Figure 14. Product Picture of Retail Pharmacies

Figure 15. Product Picture of Online Pharmacies

Figure 16. Global Transthyretin Amyloidosis Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 17. Global Transthyretin Amyloidosis Treatment Sales Value Market Share by Application, 2023 & 2030

Figure 18. North America Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)

Figure 19. North America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

Figure 20. Europe Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)

Figure 21. Europe Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

Figure 22. Asia Pacific Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)

Figure 23. Asia Pacific Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

Figure 24. South America Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)

Figure 25. South America Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

Figure 26. Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value (2019-2030) & (US$ Million)

Figure 27. Middle East & Africa Transthyretin Amyloidosis Treatment Sales Value by Country (%), 2023 VS 2030

Figure 28. Key Countries/Regions Transthyretin Amyloidosis Treatment Sales Value (%), (2019-2030)

Figure 29. United States Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 30. United States Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

Figure 31. United States Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030

Figure 32. Europe Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 33. Europe Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

Figure 34. Europe Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030

Figure 35. China Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 36. China Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

Figure 37. China Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030

Figure 38. Japan Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 39. Japan Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

Figure 40. Japan Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030

Figure 41. South Korea Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 42. South Korea Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

Figure 43. South Korea Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030

Figure 44. Southeast Asia Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 45. Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

Figure 46. Southeast Asia Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030

Figure 47. India Transthyretin Amyloidosis Treatment Sales Value, (2019-2030) & (US$ Million)

Figure 48. India Transthyretin Amyloidosis Treatment Sales Value by Type (%), 2023 VS 2030

Figure 49. India Transthyretin Amyloidosis Treatment Sales Value by Application (%), 2023 VS 2030

Figure 50. Transthyretin Amyloidosis Treatment Industrial Chain

Figure 51. Transthyretin Amyloidosis Treatment Manufacturing Cost Structure

Figure 52. Channels of Distribution (Direct Sales, and Distribution)

Figure 53. Bottom-up and Top-down Approaches for This Report

Figure 54. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Transthyretin amyloid cardiomyopathy ATTR CM Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Transthyretin Market Research Report 2024

Global Amyloidosis Therapeutics Market Research Report 2024

Global Amyloid Oligomer Market Research Report 2024

Prion Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Proteinuria Treatment Market Insights Forecast to 2030

Global Beta amyloid Peptide Market Research Report 2025

Abetalipoproteinemia Management Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Alzheimer Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Rett Syndrome Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Transverse Myelitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Huntingtons Disease Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Carasil Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Systemic Amyloidosis Market Research Report 2024

Down Syndrome Diagnosis and Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Kidney Fibrosis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Retinal Degenerative Disease Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Hemoglobinopathy Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Biologic Therapeutic Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions